United Therapeutics Corporation is a biotechnology firm focused on creating innovative treatments for patients with chronic and life-threatening diseases worldwide. It specializes in therapies for pulmonary arterial hypertension (PAH), offering a range of products including inhaled solutions, tablets, and injections to improve exercise capacity and delay disease progression. Additionally, the company works on high-risk neuroblastoma treatments and is developing new technologies for subcutaneous drug delivery and gene therapy. Founded in 1996 and based in Silver Spring, Maryland, United Therapeutics is also exploring organ xenografts and has several strategic partnerships for product development.
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology earnings and…
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on…
United Therapeutics (NASDAQ:UTHR | UTHR Price Prediction) surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data triggered price target raises from two major Wall Street firms.…
Joel South Tuesday's top analyst upgrades and downgrades included CrowdStrike, Diamondback Energy, DoorDash, Etsy, JetBlue Airways, Lululemon Athletica, Marriott International and Silvergate Capital.
Tuesday's top analyst upgrades and downgrades included Adobe, Cheniere Energy, CNX Resources, Edwards Lifesciences, EOG Resources, Huntsman, Kraft Heinz, NCR, Peloton Interactive, PulteGroup, Take-Two Interactive Software and UDR.
Tuesday's top analyst upgrades and downgrades included Accenture, Altria, American Airlines, APA, Bumble, Chevron, Datadog, General Motors, Mastercard, Pinduoduo, Regeneron Pharmaceuticals, Tesla, Toast and TotalEnergies.
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic…
Thursday's top analyst upgrades, downgrades and initiations included AbbVie, Biogen, Cree, Etsy, Gilead Sciences, Pfizer, Rite Aid, Solar Edge, Square, 3D Systems and Virgin Galactic.
Credit Suisse and Merrill Lynch made calls in the biotech and pharmaceutical space last week, ahead of coming earnings reports.
The top analyst upgrades, downgrades and initiations on Monday included Apple, Carnival, Generac, Lyft, Six Flags, Square, Tecnoglass, Yum! Brands, Western Digital and Zoetis.
The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Atlassian, Match, NextEra Energy, Nordstom, Office Depot, Roku, Stamps.com and Tanger Factory Outlet Centers.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Alcoa, Apple, Autodesk, BB&T, Bed Bath & Beyond, Camping World, Nvidia, Vertex Pharmaceuticals and Voya Financial.
Arena Pharmaceuticals shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics.
MannKind shares are continuing their rally from Tuesday when it was announced that United Therapeutics was licensing MannKind a dry powder formulation of treprostinil, the active ingredient in Remodulin.
SteadyMed saw its shares skyrocket early on Monday after the company announced that it would be acquired by United Therapeutic.
Chris Lange 
